Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp

Jess F Peterson; Michael A Pfaller; Daniel J Diekema; Michael G Rinaldi; Katherine M Riebe; Nathan A Ledeboer

doi:10.1128/JCM.02517-10

Back

Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp

Journal article

Open access

Peer reviewed

Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp

Jess F Peterson, Michael A Pfaller, Daniel J Diekema, Michael G Rinaldi, Katherine M Riebe and Nathan A Ledeboer

Journal of clinical microbiology, Vol.49(5), pp.1765-1771

05/2011

DOI: 10.1128/JCM.02517-10

PMCID: PMC3122687

PMID: 21430096

Files and links (1)

url

https://doi.org/10.1128/JCM.02517-10View

Published (Version of record) Open Access

Abstract

The performance of the automated Vitek 2 (bioMérieux, Inc., Marcy l'Etoile, France) antifungal susceptibility system was compared to that of broth microdilution (BMD) for the determination of MICs of various antifungal drugs. A total of 112 challenge strains and 755 clinical isolates of Candida spp. were tested against caspofungin and micafungin. An additional 452 clinical isolates of Candida albicans were tested against posaconazole. Reference BMD MIC endpoints were established after 24 h of incubation for caspofungin and micafungin and after 48 h of incubation for posaconazole. Essential agreements (EAs) between the Vitek 2 and BMD methods for caspofungin and micafungin were 99.5% and 98.6%, respectively. EA between the Vitek 2 and BMD methods was 95.6% for posaconazole. The overall categorical agreements (CAs) between the Vitek 2 system and BMD were 99.8% for caspofungin, 98.2% for micafungin, and 98.1% for posaconazole. The Vitek 2 system reliably determined caspofungin and micafungin MICs among Candida spp. and posaconazole MICs among C. albicans isolates and demonstrated excellent quantitative and qualitative agreement with the reference BMD method.

Antifungal Agents - pharmacology

Triazoles - pharmacology

Lipopeptides - pharmacology

United States

Humans

Automation - methods

Candida - drug effects

Microbial Sensitivity Tests - methods

Echinocandins - pharmacology

Details

Title: Subtitle: Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp
Creators: Jess F Peterson - Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA. nledeboe@mcw.edu
Michael A Pfaller
Daniel J Diekema
Michael G Rinaldi
Katherine M Riebe
Nathan A Ledeboer
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.49(5), pp.1765-1771
Publisher: United States
DOI: 10.1128/JCM.02517-10
PMID: 21430096
PMCID: PMC3122687
ISSN: 1098-660X
eISSN: 1098-660X
Language: English
Date published: 05/2011
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986374202771

Metrics

13 Record Views

28 Times Cited - Web of Science

See more details